1. Introduction {#sec1}
===============

Coronary heart disease (CHD) has become the leading cause of death in both men and women worldwide \[[@B1]\]. Most CHD-related deaths occur in individuals older than 65 years of age. The spectrum of CHD includes subclinical CHD, chronic stable angina pectoris, unstable angina, and acute myocardial infarction. A large number of elderly patients have asymptomatic heart disease; therefore, the prevalence of CHD may be underestimated \[[@B2]\]. Several large prospective clinical studies \[[@B3]--[@B7]\] have demonstrated that CHD is significantly associated with atrial fibrillation, congestive heart failure, stroke, and other serious diseases. Hence, it is important to develop effective therapies to mitigate the progression of this disease.

Suxiao jiuxin pills are one of the most commonly used Chinese medicines for cardiocerebral vascular conditions. They were first developed by Chinese medicine specialist Chenggui Zhang in the 1980s and manufactured by the Sixth Chinese Drugs Factory of Tianjin Zhongxin Pharmaceutical Co., Ltd. \[[@B8], [@B9]\]. Small doses of suxiao jiuxin pill have been shown to rapidly relieve angina pectoris and improve its symptoms without any obvious side effects. Several reports have suggested that suxiao jiuxin pill helps lower the patients\' lipid profile and improve myocardial function \[[@B10]\]. The main components of suxiao jiuxin pills are borneol and*Ligusticum chuanxiong* Hort \[[@B9], [@B11]--[@B15]\]. These ingredients can effectively induce relaxation and inhibit artery contraction \[[@B9], [@B11]\]. In addition, several smaller clinical studies have been conducted to study the efficacy of suxiao jiuxin pill on CHD patients; however, these results have been inconsistent \[[@B16]--[@B19]\]. Cao and Zhang suggested that suxiao jiuxin pill was associated with symptom remission, reduced incidence of angina, and shorter duration of angina. Further, electrocardiogram results were significantly improved by nitroglycerin use compared with salvia \[[@B16]\]. Qiao et al. demonstrated that suxiao jiuxin pills plus trimetazidine therapy significantly reduced the effective rate of angina, but other relevant indices were not evaluated \[[@B17]--[@B19]\]. Clarifying the beneficial and harmful effects of suxiao jiuxin pill is particularly important for CHD patients, as they have not been distinctly determined with respect to ECG results, lipid profiles, hemorheology, and adverse reactions. Therefore, we performed a large-scale meta-analysis of the available randomized controlled trials to determine the benefits of suxiao jiuxin pill for CHD patients.

2. Materials and Methods {#sec2}
========================

Ethical approval and written consent were not necessary for the meta-analysis, as the data was collected from published literature.

Our meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@B20]\]. We searched the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases to identify relevant studies published in English or Chinese prior to June 2016. Our search terms included "coronary heart disease," "suxiao jiuxin pill," and "coronary artery disease." We also searched for meta-analysis publications and bibliographies referenced in the selected publications. Gray literature was identified through related agencies and clinical trial registers. Clinical trials that compared the efficacy of suxiao jiuxin pill on coronary heart disease with those of placebo or standard therapy were included in this meta-analysis. Criteria for inclusion were as follows: (1) a randomized controlled study design, (2) the possibility of extracting accurate clinical data, (3) classifying coronary heart disease based on the updated guidelines of the American Heart Association and American College of Cardiology Foundation \[[@B21], [@B22]\], and (4) reporting ECG results, lipid profiles, and/or hemorheology changes as outcomes. Two reviewers (X. L. H. and J. Z. J.) independently reviewed the studies to determine whether they satisfied the eligibility criteria. Discrepancies between reviewers\' opinions were resolved by consensus, and a third reviewer was consulted when necessary.

2.1. Data Extraction {#sec2.1}
--------------------

Two independent reviewers using the same checklist evaluated the data from the included studies. Disagreements between the reviewers were resolved by discussion until consensus was reached. The following sets of data were extracted for each selected study when available: demographics and sample characteristics, definition of coronary heart disease, and usage of suxiao jiuxin pill. The primary outcome of the selected studies was the improvement in ECG results, including resting ECG returning to normal or negative submaximal exercise test. The secondary outcomes included changes in lipid profile (total cholesterol, total triglyceride, low-density lipoprotein, and high-density lipoprotein) and hemorheology (high-cut whole blood viscosity, low-cut whole blood viscosity, plasma viscosity, hematocrit, and fibrinogen) as well as any adverse reactions.

2.2. Quality Assessment {#sec2.2}
-----------------------

Two reviewers independently assessed the methodological quality of the studies using the Jadad scoring system \[[@B23]\]. Five aspects for each study were thoroughly evaluated: the statement of randomization, the method used for generating randomized sequences for treatment assignments, the use of double-blind design, the description of the double blinding method, and data on withdrawals and dropouts. Studies with a score less than 3 were considered as low quality studies with high bias risk. Studies that received a score of 3 or greater were considered as high-quality studies. Disagreements between the reviewers were resolved by consensus and consultation with a third reviewer when necessary.

2.3. Data Analysis {#sec2.3}
------------------

Continuous variables, such as changes in lipid profiles and hemorheology, were expressed as mean ± standard deviation. Categorical data, such as ECG result improvement and adverse reaction incidence, were presented as frequencies and percentages. We computed the pooled relative risk (RR), weighted mean difference (WMD), and 95% confidence interval (CI), as well as the heterogeneity of the included studies by using random-effect (DerSimonian and Laird) models. Metaregression analysis was conducted based on sample size and mean age to explore the impact of sample size on the source of heterogeneity \[[@B24]\]. We also performed subgroup analyses to compare the efficacy of different drugs with those of suxiao jiuxin pill on ECG result improvement. Heterogeneity was quantified using the *I*^2^ statistic. We considered *I*^2^ values greater than 50% to indicate significant heterogeneity between the studies. Statistical heterogeneity between studies was also formally tested with the Cochran test (*P* \< 0.10) \[[@B25], [@B26]\]. Publication bias was evaluated using the funnel plot and Egger\'s and Begg tests, with *P* values less than 0.05 considered significant publication bias. Two-tailed *P* values less than 0.05 were considered statistically significant. All statistical analyses were performed with STATA 12.0 (Stata Corporation, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

The search strategy revealed 1515 potentially eligible publications. After duplicate removal, 1253 studies remained. Abstracts were evaluated based on the inclusion and exclusion criteria. 85 studies warranting further review were identified. Among these, 44 studies were excluded for the reasons listed in [Figure 1](#fig1){ref-type="fig"}. The remaining 41 studies were included in our meta-analysis. Journal articles and full manuscripts were obtained for all 41 studies.

3.2. Study Characteristics {#sec3.2}
--------------------------

The characteristics of the trials included in our meta-analysis are presented in [Table 1](#tab1){ref-type="table"}. All of the included studies were conducted in China. The following studies were included as the control group: 2 studies involving standard treatment \[[@B27], [@B28]\], 7 studies involving nitroglycerin (using various formulations) \[[@B29]--[@B35]\], 12 studies involving isosorbide dinitrate \[[@B36]--[@B47]\], 11 studies involving salvia tablets \[[@B16], [@B17], [@B48]--[@B56]\], and 9 studies involving Chinese herbal pills other than suxiao jiuxin \[[@B18], [@B32], [@B57]--[@B64]\].

The 41 studies consisted of 6276 patients with coronary heart disease. The mean age in the treatment group was 57.57 ± 8.15 years and 54.10% of the patients were male. The mean age in the control group was 57.80 ± 8.72 years and 45.96% of the patients were male. The baseline characteristics were balanced between the treatment and control groups. The majority of the included studies received low Jadad scores due to the lack of a double-blind design ([Table 2](#tab2){ref-type="table"}).

3.3. ECG Result Improvement {#sec3.3}
---------------------------

[Figure 2](#fig2){ref-type="fig"} presents the results of the meta-analysis of ECG improvement following administration of suxiao jiuxin pills. ECG results were reported in 35 studies. Pooled analysis indicated significant benefits of suxiao jiuxin pill on ECG outcomes (RR 1.32; 95% CI 1.26 to 1.38, *P* \< 0.001). However, there was significant heterogeneity between studies with respect to ECG results (*I*^2^ = 62.3%). Findings from the meta-regression analyses suggested that sample size and mean age of the patients were not significant factors contributing to the association between suxiao jiuxin pills and ECG outcomes ([Table 3](#tab3){ref-type="table"}). Considering that the control group may be the source of the heterogeneity, we performed subgroup analyses to compare the effects of suxiao jiuxin pill with those of control treatment ([Figure 3](#fig3){ref-type="fig"}). The subgroup analyses indicated that suxiao jiuxin pill improved ECG results more than salvia tablets (RR 1.54; 95% CI 1.41 to 1.67, *P* \< 0.001), isosorbide dinitrate (RR 1.14; 95% CI 1.05 to 1.22, *P* = 0.001), nitroglycerin (RR 1.35, 95% CI 1.16 to 1.56, *P* \< 0.001), and other drugs (RR 1.32, 95% CI 1.21 to 1.44, *P* \< 0.001). The *I*^2^ decreased to 39.1% in the nitroglycerin subgroup. However, moderate heterogeneity was still observed among the other three subgroups (*I*^2^ = 50.0%, 44.9%, and 43.6%, resp.). Sensitivity analysis was conducted by excluding individual studies one after another but did not reveal a substantial change in the overall trend of heterogeneity between studies. We also constructed a funnel plot to assess the degree of publication bias. The funnel plot was symmetrically distributed around the pooled effect size, which indicated the absence of significant publication bias in the included studies ([Figure 4](#fig4){ref-type="fig"}). In addition, examining the funnel plot asymmetry via Egger test (*P* = 0.067) and Begg test (*P* = 0.050) did not demonstrate publication bias.

3.4. Lipid Profile {#sec3.4}
------------------

Only four of the studies reported the efficacy of suxiao jiuxin pill on patients\' lipid profiles, and they all reported the total cholesterol in the patients\' serum \[[@B33], [@B55], [@B57], [@B63]\]. Significant lower total cholesterol levels were reported in the suxiao jiuxin pill group compared with the control group (WMD −0.62 mmol/L, 95% CI −1.06 to --0.18 mmol/L, and *P* = 0.005). There was significant heterogeneity among the 4 studies with respect to total cholesterol levels (*I*^2^ = 77.1%) (Supplemental [Figure S1](#supplementary-material-1){ref-type="supplementary-material"}). In addition, the four studies reported total triglyceride levels in the patients\' serum \[[@B33], [@B55], [@B57], [@B63]\]. There was no significant difference in WMD between the treatment and control groups (WMD −0.59 mmol/L, 95% CI −1.72 to 0.54 mmol/L, and *P* = 0.303). We detected significant heterogeneity between studies among the 4 studies with respect to total triglyceride levels (*I*^2^ = 98.2%) (Supplemental [Figure S2](#supplementary-material-1){ref-type="supplementary-material"}). Three of the studies reported LDL levels \[[@B33], [@B57], [@B63]\]. There were significantly lower LDL levels in the treatment group compared with the control group (WMD −1.12 mmol/L, 95% CI −1.42 to −0.82 mmol/L, and *P* \< 0.001) and lower heterogeneity between the 3 trials (*I*^2^ = 56.5%) (Supplemental [Figure S3](#supplementary-material-1){ref-type="supplementary-material"}). Furthermore, the four studies reported HDL levels \[[@B30], [@B52], [@B54], [@B60]\]. There were significantly higher HDL levels in the treatment group compared with the control group (WMD 0.32 mmol/L, 95% CI 0.07 to 0.58 mmol/L, and *P* = 0.014), however with significant heterogeneity with respect to HDL levels (*I*^2^ = 87.5%) (Supplemental [Figure S4](#supplementary-material-1){ref-type="supplementary-material"}). Sensitivity analysis did not reveal any single study as the source of heterogeneity. We did detect sample size (*P* = 0.013) as a contribution to the association between suxiao jiuxin pill and total triglyceride level, with no other significant factors being observed ([Table 3](#tab3){ref-type="table"}).

3.5. Hemorheology {#sec3.5}
-----------------

Six studies reported the levels of low-cut whole blood viscosity after treatment \[[@B39], [@B41], [@B43], [@B53], [@B57], [@B63]\]. There were significantly lower low-cut whole blood viscosity levels in the treatment group compared to the control group (WMD −1.57 mpa·s, 95% CI −2.50 to −0.65 mpa·s, and *P* = 0.001). Significant heterogeneity was observed among these studies with respect to the level of low-cut whole blood viscosity (*I*^2^ = 86.8%) (Supplemental [Figure S5](#supplementary-material-1){ref-type="supplementary-material"}). Six studies reported the levels of high-cut whole blood viscosity \[[@B39], [@B41], [@B43], [@B53], [@B57], [@B63]\], which were significantly lower in the treatment group (WMD −0.69 mpa·s, 95% CI −1.03 to −0.34 mpa·s, and *P* \< 0.001). Significant heterogeneity was also observed among these studies with respect to the level of high-cut whole blood viscosity (*I*^2^ = 87.6%) (Supplemental [Figure S6](#supplementary-material-1){ref-type="supplementary-material"}). Seven studies reported the levels of plasma viscosity \[[@B33], [@B39], [@B41], [@B43], [@B54], [@B57], [@B63]\]. There was no significant difference in WMD between the treatment and control groups (WMD −0.03 mpa·s, 95% CI −0.07 to 0.01 mpa·s, and *P* = 0.186) and no significant heterogeneity between studies among these studies with respect to the level of plasma viscosity (*I*^2^ = 4.9%) (Supplemental [Figure S7](#supplementary-material-1){ref-type="supplementary-material"}). Four studies reported the levels of hematocrit \[[@B33], [@B54], [@B57], [@B63]\] and no significant differences were observed in WMD between the treatment and control groups (WMD −1.24%, 95% CI −3.26 to 0.77%, and *P* = 0.227). There was significant heterogeneity among three studies with respect to the level of hematocrit (*I*^2^ = 84.3%) (Supplemental [Figure S8](#supplementary-material-1){ref-type="supplementary-material"}). Four studies reported the levels of fibrinogen \[[@B33], [@B53], [@B57], [@B63]\] with no significant difference in WMD between the treatment and control groups (WMD −0.76 g/L, 95% CI −1.32 to −0.20 g/L, and *P* = 0.008). There was significant heterogeneity among the three studies with respect to the fibrinogen level (*I*^2^ = 85%) (Supplemental [Figure S9](#supplementary-material-1){ref-type="supplementary-material"}). Sensitivity analysis was conducted by excluding each study individually and showed no substantial change in the overall trend. Furthermore, sample size and mean age were not correlated with treatment efficacy of suxiao jiuxin pills on hemorheology ([Table 3](#tab3){ref-type="table"}).

3.6. Adverse Reactions {#sec3.6}
----------------------

Fourteen studies reported the incidence of adverse reactions. The most common symptoms were mild headache, dizziness, and facial flushing. Most of these symptoms resolved spontaneously. There was no significant difference in the adverse reaction rates between the treatment and the control groups (RR 1.12, 95% CI 0.50 to 2.51, and *P* = 0.785) and no significant heterogeneity with respect to adverse reaction rate (*I*^2^ = 49.1%) (Supplemental [Figure S10](#supplementary-material-1){ref-type="supplementary-material"}). Additionally, meta-regression analyses suggested that both sample size and mean age were not associated with adverse reaction in the suxiao jiuxin pill treatment group ([Table 3](#tab3){ref-type="table"}). The funnel plot was symmetrically distributed around the pooled effect size, which indicated the absence of significant publication bias in the included studies (Supplemental [Figure S11](#supplementary-material-1){ref-type="supplementary-material"}). In addition, no publication bias was identified using the Egger test (*P* = 0.064) or Begg test (*P* = 0.274).

4. Discussion {#sec4}
=============

Based on our meta-analysis, we found that suxiao jiuxin pills could significantly improve ECG results in CHD patients compared with other therapies used in the selected studies. Suxiao jiuxin pills decreased the levels of total cholesterol and LDL, increased the levels of HDL, and lowered low-cut and high-cut whole blood viscosity. Other hemorheology-related parameters, such as plasma viscosity, hematocrit, and fibrinogen, showed the same tendency, but these changes were not statistically significant.

In recent years, several randomized clinical trials have been performed to evaluate the efficacy of suxiao jiuxin pill on CHD patients \[[@B17], [@B27], [@B28], [@B56]\]. Long studied 120 patients with unstable angina and found that suxiao jiuxin pills significantly improved both ECG results and symptoms compared with standard treatment \[[@B28]\]. Bu evaluated the benefits of suxiao jiuxin pills with isosorbide dinitrate on one hundred coronary heart disease (CAD) patients \[[@B44]\]. However, they did not find any significant differences between the groups with respect to ECG result improvement and angina relief. This may be due to the small sample size, different inclusion criteria, and differences in treatment strategy.

Two previous meta-analyses that explored the efficacy of suxiao jiuxin pills on CHD \[[@B65], [@B66]\] found them to be effective in the treatment of angina pectoris, without any serious side effects. However, due to the limited sample sizes, low quality of the studies, and other potential confounding factors, the asymmetry funnel plot demonstrated the lack of reliability of these meta-analyses \[[@B65], [@B66]\]. As a result, we conducted this updated meta-analysis of randomized controlled trials to further clarify the effects of suxiao jiuxin pills on CHD patients.

Suxiao jiuxin pills have been widely used in China for many years in patients with angina. It has two main effective components, borneol and*Ligusticum chuanxiong* Hort, which can be found mainly in the Sichuan province of China.*Ligusticum chuanxiong* Hort was first described in the \'Divine Husbandman\'s Materia Medica.\'*L. chuanxiong* has long been regarded as a traditional Chinese medicine and has been added to food for its health benefits. The main chemical components of*L. chuanxiong* include essential oils, phenolic acids, and phthalide lactones \[[@B67], [@B68]\]. Several researchers have demonstrated that*L. chuanxiong* could lower serum cholesterol and lipoprotein levels, reduce red blood cell deformability, and relieve angiotensin II--induced vascular smooth muscle cell proliferation. These unique roles may be due to the increase in nitric oxide and suppression of nuclear factor-*κ*B activation \[[@B69], [@B70]\]. In addition,*L. chuanxiong* has a direct vasodilatory effect on isolated aortic rings in rats \[[@B71]\]. The mechanisms of this effect are related to the opening of SK (Ca) and ATP~K~ channels, the reduction of ET-1, and the formation of reactive oxygen species (ROS) \[[@B72], [@B73]\]. Recent evidence has suggested that*L. chuanxiong* may exert antiplatelet effects by inhibiting the vWF-mediated process of platelet thrombus formation.

Borneol is a fragrant ingredient used in decorative cosmetics and is widely regarded as an adjuvant in Chinese herbs \[[@B74]\]. Several animal studies have demonstrated that borneol can dilate coronary arteries and improve coronary circulation. In addition, studies have demonstrated that borneol can inhibit the inflammatory response in animal models \[[@B75]\]. As a result, borneol is widely used in China for the treatment of CHD patients in clinical practice.

We found that the main side effects of suxiao jiuxin pills were mild headaches, dizziness, and facial flushing, all of which resolved spontaneously. The adverse reaction incidence associated with suxiao jiuxin pill was not significantly different from those associated with other treatments. Evidence suggests that suxiao jiuxin pills are safe with no adverse effects.

As in many meta-analyses, there were several limitations to our study. Most of the clinical studies included in our meta-analysis were of poor quality based on their Jadad scores. Only a few studies reported detailed research methodology, a factor that could decrease the reliability of this meta-analysis. In addition, all of the included studies were from Chinese publications, and this may be a source of bias. Significant heterogeneity between studies was noted in our meta-analysis even after subgroup analysis. Different study quality, sample size, usage of suxiao jiuxin pill, and control groups may contribute to this heterogeneity. In this study, we did not analyze cardiovascular death or drug-related complications.

In summary, our meta-analysis demonstrated that suxiao jiuxin pills improved ECG results and lipid profiles better compared with nitroglycerin, isosorbide dinitrate, salvia, and other Chinese herbal pills. They also decreased low-cut and high-cut whole blood viscosity.

5. Conclusions {#sec5}
==============

Suxiao jiuxin pills can effectively decrease the lipid profiles and improve hemorheology parameters in CHD patients. This is due to the effects of their components (borneol and*L. chuanxiong*), which may improve coronary artery circulation and ECG results.
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![Process used to select relevant studies for inclusion in the meta-analysis.](ECAM2018-9745804.001){#fig1}

![Relative risks for ECG improvement in the treatment and control groups.](ECAM2018-9745804.002){#fig2}

![Relative risks for ECG improvement in the various subgroups.](ECAM2018-9745804.003){#fig3}

![Funnel plot of studies included in the meta-analysis.](ECAM2018-9745804.004){#fig4}

###### 

Characteristics of selected clinical trials included in the meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author name     Year   Sample size   Study design   Age             Age             Country   Comparators                         Dosage/frequency/cycle   Outcomes       Follow-up period                                  
  --------------- ------ ------------- -------------- --------------- --------------- --------- ----------------------------------- ------------------------ -------------- ------------------------------------------------- -------------
  He              1995   48            RCT            42--60          40--57          China     Salvia                              4\# tid                  3\# tid        Hemorheology                                      4 weeks

                                                                                                                                                                                                                              

  Song            1995   149           RCT            55 ± 7.2        56 ± 6.9        China     Salvia                              5\# tid                  3\# tid        ECG, blood pressure, and heart rate               4 weeks

                                                                                                                                                                                                                              

  Wang            1996   60            RCT            NR              NR              China     Shexiang Baoxin pills               5\# tid                  3\# tid        ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Ke              1996   72            RCT            45--79          46--78          China     Nitroglycerin                       6\# tid                  0.5 mg Q8 h    ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Gao et al.      1996   147           RCT            36--85          35--84          China     Nitroglycerin                       10\#                     0.5 mg         ECG and symptom                                   Immediately

                                                                                                                                                                                                                              

  Yun             1996   318           RCT            44--76          44--75          China     Isosorbide dinitrate                6--10\#\                 10\# tid       ECG and symptom                                   2 weeks
                                                                                                                                    Q4--6 h                                                                                   

                                                                                                                                                                                                                              

  Li              1998   154           RCT            58.93 ± 10.91   59.25 ± 10.12   China     Isosorbide dinitrate                0.2 g tid                10\# tid       ECG and symptom                                   8 weeks

                                                                                                                                                                                                                              

  Feng and Zhou   2000   500           RCT            56 ± 4.24       55 ± 4.36       China     Salvia                              10\# tid                 10\# tid       ECG and symptom, Lipid profile and hemorheology   4 weeks

                                                                                                                                                                                                                              

  Mei             2000   128           RCT            NR              NR              China     Isosorbide dinitrate                6\# tid                  10\# tid       ECG, symptom, and hemorheology                    4 weeks

                                                                                                                                                                                                                              

  Xiao            2000   138           RCT            NR              NR              China     Isosorbide dinitrate                5\# tid                  10\# tid       ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Ru              2000   90            RCT            45--70          NR              China     Salvia                              5\# tid                  3\# tid        ECG, symptom, lipid profile, and hemorheology     Unclear

                                                                                                                                                                                                                              

  Shu             2000   80            RCT            58.3 ± 7.24     57.2 ± 8.27     China     Isosorbide dinitrate                10\# tid                 10\# tid       ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Yong            2000   148           RCT            45--72          47--70          China     Nitroglycerin                       10\#                     5 mg           ECG, Symptom, blood pressure, and heart rate      Immediately

                                                                                                                                                                                                                              

  Guang           2000   248           RCT            NR              NR              China     Isosorbide dinitrate                5\# tid                  10\# tid       Blood pressure, heart rate, and lipid profile     4 weeks

                                                                                                                                                                                                                              

  Li              2000   166           RCT            NR              NR              China     Nitroglycerin                       5\# tid                  0.5 mg         ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Yu              2000   184           RCT            40--82          NR              China     Isosorbide dinitrate                5\# tid                  10\# tid       ECG and symptom                                   15 days

                                                                                                                                                                                                                              

  Ya              2000   60            RCT            60--84          61--84          China     Nitroglycerin                       5\# tid                  10\# tid       ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Yuan            2000   102           RCT            61.68 ± 4.71    59.53 ± 5.62    China     Huoxin pills                        5\# tid                  1\# tid        ECG, symptom, and lipid profile                   4 weeks

                                                                                                                                                                                                                              

  Duan and Yang   2002   80            RCT            42--79          41--75          China     Xinkeshu capsule                    5\# tid                  4\# tid        ECG, UCG, lipid profile, and hemorheology         4 weeks

                                                                                                                                                                                                                              

  Hai             2002   70            RCT            57 ± 7          59 ± 6          China     Isosorbide dinitrate                5\# tid                  10\# tid       Symptom and hemorheology                          4 weeks

                                                                                                                                                                                                                              

  Bu              2002   100           RCT            32--72          NR              China     Isosorbide dinitrate                4--6\# tid               10--20\# tid   ECG and symptom                                   Unclear

                                                                                                                                                                                                                              

  Pei             2003   102           RCT            56.1            55.2            China     Nitroglycerin                       5\# tid                  Unclear        ECG, lipid profile, and hemorheology              8 weeks

                                                                                                                                                                                                                              

  Jin             2003   178           RCT            NR              NR              China     Isosorbide dinitrate                5\# tid                  20 mg qd       ECG, Symptom, lipid profile, and hemorheology     6 weeks

                                                                                                                                                                                                                              

  Ma              2004   116           RCT            63.4 ± 6.74     62.9 ± 7.84     China     Salvia                              10\# tid                 3\# tid        ECG, symptom, and hemorheology                    4 weeks

                                                                                                                                                                                                                              

  Pei             2004   100           RCT            57.5 ± 10.2     63.1 ± 7.9      China     Xinkeshu capsule                    6\# tid                  4\# tid        ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Yue             2004   78            RCT            52--75          55--74          China     Placebo                             5\# tid                  10\# tid       ECG, UCG, and symptom                             4 weeks

                                                                                                                                                                                                                              

  Hu              2004   80            RCT            51.56 ± 11.69   50.89 ± 11.02   China     Nitroglycerin                       10\# tid                 0.5 mg tid     ECG and symptom                                   24 weeks

                                                                                                                                                                                                                              

  Zhu             2005   199           RCT            61.8            59.5            China     Glucose-insulin-potassium therapy   4--6\# tid               Q2 d           ECG, symptom, and lipid profile                   15 days

                                                                                                                                                                                                                              

  Wan             2005   64            RCT            NR              NR              China     Hesu pills                          5\# tid                  1\# tid        ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Shui            2006   73            RCT            43--78          45--76          China     Salvia                              10\# tid                 10\# tid       ECG and lipid profile                             8 weeks

                                                                                                                                                                                                                              

  Cao and Zhang   2007   187           RCT            57.15 ± 5.38    58.77 ± 5.01    China     Salvia                              6\# tid                  6\# tid        ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Run             2007   90            RCT            NR              NR              China     Isosorbide dinitrate                10--15\#                 10 mg          ECG and symptom                                   Immediately

                                                                                                                                                                                                                              

  Wang            2008   60            RCT            63.9 ± 12.1     64.1 ± 11.2     China     Shexiang Baoxin pills               5\# tid                  1\# tid        ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  L. Wen          2009   88            RCT            56.7            56.8            China     Isosorbide dinitrate                5\# tid                  10\# tid       ECG and symptom                                   8 weeks

                                                                                                                                                                                                                              

  Feng            2009   900           RCT            NR              NR              China     Salvia                              6\# tid                  3\# tid        ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  S. L. Wen       2009   50            RCT            NR              NR              China     Tongxinluo pills                    5\# tid                  4\# tid        ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Guo             2012   60            RCT            42--70          43--73          China     Salvia                              5\# tid                  3\# tid        UCG and hemorheology                              2 weeks

                                                                                                                                                                                                                              

  Qiao            2012   300           RCT            39--82          40--81          China     Salvia                              5\# tid                  3\# tid        ECG and symptom                                   4 weeks

                                                                                                                                                                                                                              

  Xin             2013   289           RCT            58.86 ± 10.57   57.69 ± 9.93    China     Standard therapy                    10\# tid                 Blank          ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Long            2013   120           RCT            43--68          42--67          China     Standard therapy                    10\# tid                 Blank          ECG and symptom                                   2 weeks

                                                                                                                                                                                                                              

  Li              2015   100           RCT            44--75          45--76          China     Salvia                              6\# tid                  3\# tid        ECG and symptom                                   4 weeks
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported; RCT: randomized controlled trial; tid: three times a day; Q4--6 h: every 4--6 h; Q8 h: every 8 h; ECG: electrocardiograph; UCG: ultrasound cardiogram; \#: tablet.

###### 

*Jadad* quality scores of selected studies.

  Author name       Randomization   Generating randomized sequences   Blinding   Withdrawals and dropouts   Overall
  ----------------- --------------- --------------------------------- ---------- -------------------------- ---------
  Guan-hua He       1               0                                 0          0                          1
  Zhi-jin Song      1               0                                 0          0                          1
  Dong-ping Wang    1               0                                 1          0                          2
  Ke-fu Ji          1               0                                 0          0                          1
  Yu-chu Gao        1               0                                 0          0                          1
  Yun-yuan Guo      1               0                                 0          0                          1
  Li An             1               0                                 0          0                          1
  Ling Feng         1               0                                 0          0                          1
  Mei Hu            1               0                                 0          1                          2
  Xiao-chun Liu     1               0                                 0          0                          1
  Ru-bao Jia        1               0                                 0          0                          1
  Shu-dong Yang     1               0                                 0          0                          1
  Yong-jin Hou      1               0                                 0          0                          1
  Guang-yu Tang     1               0                                 0          0                          1
  Li-jun Zhou       1               0                                 0          0                          1
  Yu-ping Li        1               0                                 0          0                          1
  Ya-xiong Zhan     1               0                                 1          0                          2
  Jing-xian Yuan    1               0                                 0          0                          1
  Ke-jie Duan       1               0                                 0          0                          1
  Hai Shi           1               0                                 0          0                          1
  Bu-ce Sun         1               0                                 0          0                          1
  Pei-ying Wu       1               0                                 0          0                          1
  Jin Gao           1               0                                 0          0                          1
  Xian-zhen Ma      1               0                                 0          0                          1
  Pei-fen Chang     1               0                                 0          0                          1
  Yue-sheng Zhao    1               0                                 0          0                          1
  Gang Hu           1               0                                 0          0                          1
  Dong-you Zhu      1               0                                 0          0                          1
  Wei Wan           1               0                                 0          0                          1
  Shui-xiang Wan    1               0                                 0          0                          1
  Sheng-hai Cao     1               0                                 0          0                          1
  Run-lian Tang     1               0                                 0          1                          2
  Fei Wang          1               0                                 0          0                          1
  Wen Luo           1               0                                 0          0                          1
  Feng-hua Song     1               0                                 0          0                          1
  Wen-sheng Li      1               0                                 1          0                          2
  Wei-qin Guo       1               0                                 0          0                          1
  Qiao-kun Xu       1               0                                 0          0                          1
  Xin He            1               0                                 0          0                          1
  Long-jiang Qian   1               0                                 0          0                          1
  Li Xiao-jin       1               0                                 0          1                          2

###### 

Metaregression based on sample size and mean age.

  Outcomes                             Sample size   Mean age
  ------------------------------------ ------------- ----------
  Electrocardiogram improvement        0.206         0.059
  Total cholesterol                    0.758         0.236
  Total triglycerides                  0.013         0.507
  Total low-density lipoprotein        0.283         0.513
  Total high-density lipoprotein       0.715         0.789
  Low-cutting whole blood Viscosity    0.917         0.774
  High-cutting whole blood Viscosity   0.412         0.621
  Plasma viscosity                     0.075         0.842
  Hematocrit                           0.049         0.490
  Fibrinogen                           0.890         0.345
  Adverse reactions                    0.554         0.772

[^1]: Academic Editor: I-Min Liu
